Romosozumab in Postmenopausal Women with Low Bone Mineral Density
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. RESULTS: All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. CONCLUSIONS: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the simultaneous, acute increase in P1NP and reduction in CTx that we observed in the T3 group is qualitatively identical (but smaller in magnitude) to the effects of sclerostin inhibition on bone markers in humans22, and arguably pathognomonic of the consequences of sclerostin inhibition on bone.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
In the citing paper
“the time course of changes in bone formation we observed over 20 weeks of intermittent D + Q treatment in the T3 group is virtually identical (albeit smaller in magnitude) to that observed following treatment with the FDA-approved sclerostin inhibitor, romosozumab, where serum P1NP increased rapidly over the first 1–4 weeks following dosing and then returned to baseline by 24 weeks22.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Cited by
Items 101–200 of 1,000
Antiresorptive and anabolic agents in the prevention and reversal of bone fragility
Seeman, E., & Martin, T. J. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0172-3 · Cited by 131
Drechsler, C., Evenepoel, P., Vervloet, M. G., Wanner, C., Ketteler, M., Marx, N., Floege, J., Dekker, F. W., Brandenburg, V. M., & for the NECOSAD Study Group (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu301 · Cited by 123
Changes in the osteocyte lacunocanalicular network with aging
Tiede-Lewis, L. M., & Dallas, S. L. (2019) · Bone · doi:10.1016/j.bone.2019.01.025 · Cited by 139
Chang, M.-K., Kramer, I., Huber, T., Kinzel, B., Guth-Gundel, S., Leupin, O., & Kneissel, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413828111 · Cited by 120
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review
Ukon, Y., Makino, T., Kodama, J., Tsukazaki, H., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102557 · Cited by 128
Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease
Hutcheson, J. D., & Goettsch, C. (2023) · Circulation Research · doi:10.1161/circresaha.123.321760 · Cited by 142
Bovijn, J., Krebs, K., Chen, C.-Y., Boxall, R., Censin, J. C., Ferreira, T., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6570 · Cited by 119
Osteoporosis in Individuals with Spinal Cord Injury
Bauman, W. A., & Cardozo, C. P. (2014) · PM&R · doi:10.1016/j.pmrj.2014.08.948 · Cited by 128
Lv, F., Cai, X., Yang, W., Gao, L., Chen, L., Wu, J., & Ji, L. (2019) · Bone · doi:10.1016/j.bone.2019.115121 · Cited by 131
Romosozumab and antiresorptive treatment: the importance of treatment sequence
Cosman, F., Kendler, D. L., Langdahl, B. L., Leder, B. Z., Lewiecki, E. M., Miyauchi, A., Rojeski, M., McDermott, M., Oates, M. K., Milmont, C. E., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06174-0 · Cited by 120
Self-citationYao, W., Dai, W., Jiang, L., Lay, E. Y.-A., Zhong, Z., Ritchie, R. O., Li, X., Ke, H., & Lane, N. E. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3308-6 · Cited by 114
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2015) · Drugs · doi:10.1007/s40265-015-0417-7 · Cited by 128
Revisiting the role of Wnt/β-catenin signaling in prostate cancer
Schneider, J. A., & Logan, S. K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.008 · Cited by 121
Bone-Targeted Therapies in Cancer-Induced Bone Disease
Sousa, S., & Clézardin, P. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0353-5 · Cited by 125
Regulation of bone homeostasis: signaling pathways and therapeutic targets
Wu, Z., Li, W., Jiang, K., Lin, Z., Qian, C., Wu, M., Xia, Y., Li, N., Zhang, H., Xiao, H.-X., et al. (2024) · MedComm · doi:10.1002/mco2.657 · Cited by 151
Targeting WNT signaling in the treatment of osteoporosis
Baron, R., & Gori, F. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.04.011 · Cited by 101
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis
Estell, E. G., & Rosen, C. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00426-5 · Cited by 120
Management of patients at very high risk of osteoporotic fractures through sequential treatments
Curtis, E. M., Reginster, J., Al‐Daghri, N. M., Biver, E., Brandi, M. L., Cavalier, E., Hadji, P., Halbout, P., Harvey, N. C., Hiligsmann, M., et al. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02100-4 · Cited by 127
Self-citationSclerostin inhibition alleviates breast cancer–induced bone metastases and muscle weakness
Hesse, E., Schröder, S., Brandt, D., Pamperin, J., Saito, H., & Taipaleenmäki, H. (2019) · JCI Insight · doi:10.1172/jci.insight.125543 · Cited by 115
Targeting Wnts at the Source—New Mechanisms, New Biomarkers, New Drugs
Madan, B., & Virshup, D. M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1038 · Cited by 114
Ishibashi, H., Crittenden, D. B., Miyauchi, A., Libanati, C., Maddox, J., Fan, M., Chen, L., & Grauer, A. (2017) · Bone · doi:10.1016/j.bone.2017.07.005 · Cited by 111
Self-citationDíez‐Pérez, A., Marín, F., Eriksen, E. F., Kendler, D. L., Krege, J. H., & Delgado‐Rodríguez, M. (2018) · Bone · doi:10.1016/j.bone.2018.09.020 · Cited by 116
Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones
Wang, J. S., Mazur, C. M., & Wein, M. N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.584147 · Cited by 130
Chandra, A., Lin, T., Young, T., Tong, W., Ma, X., Tseng, W.-J., Kramer, I., Kneissel, M., Levine, M. A., Zhang, Y., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2996 · Cited by 115
New Insights into Monogenic Causes of Osteoporosis
Mäkitie, R. E., Costantini, A., Kämpe, A., Alm, J. J., & Mäkitie, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00070 · Cited by 108
Suen, P. K., & Qin, L. (2015) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2015.08.004 · Cited by 123
Mechanical Load Increases in Bone Formation via a Sclerostin-Independent Pathway
Morse, A., McDonald, M. M., Kelly, N. H., Melville, K. M., Schindeler, A., Krämer, I., Kneissel, M., van der Meulen, M. C. H., & Little, D. G. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2278 · Cited by 120
Lyons, J. S., Joca, H. C., Law, R. A., Williams, K. M., Kerr, J. P., Shi, G., Khairallah, R. J., Martin, S. S., Konstantopoulos, K., Ward, C. W., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aan5748 · Cited by 106
Taylor, S., Ominsky, M. S., Hu, R., Pacheco, E., He, Y. D., Brown, D. L., Aguirre, J. I., Wronski, T. J., Buntich, S., Afshari, C. A., et al. (2016) · Bone · doi:10.1016/j.bone.2015.12.013 · Cited by 106
Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta
Roschger, A., Roschger, P., Keplingter, P., Klaushofer, K., Abdullah, S., Kneissel, M., & Rauch, F. (2014) · Bone · doi:10.1016/j.bone.2014.06.015 · Cited by 108
Sanz-Salvador, L., García‐Pérez, M. Á., Tarín, J. J., & Cano, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0424 · Cited by 119
Ominsky, M. S., Boyd, S. K., Varela, A., Jolette, J., Felx, M., Doyle, N., Mellal, N., Smith, S. Y., Locher, K., Buntich, S., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3036 · Cited by 103
Keaveny, T. M., Crittenden, D. B., Bolognese, M. A., Genant, H. K., Engelke, K., Oliveri, B., Brown, J. P., Langdahl, B. L., Yan, C., Grauer, A., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3176 · Cited by 102
Self-citationNovel actions of sclerostin on bone
Holdsworth, G., Roberts, S. J., & Ke, H. Z. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0176 · Cited by 118
Wnt signaling and osteoporosis
Manolagas, S. C. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.04.013 · Cited by 114
Loh, N. Y., Neville, M. J., Marinou, K., Hardcastle, S. A., Fielding, B. A., Duncan, E. L., McCarthy, M. I., Tobias, J. H., Gregson, C. L., Karpe, F., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.009 · Cited by 104
Romosozumab for the treatment of osteoporosis
Bandeira, L., Lewiecki, E. M., & Bilezikian, J. P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1280455 · Cited by 101
Fulzele, K., Lai, F., Dedic, C., Saini, V., Uda, Y., Shi, C., Tuck, P., Aronson, J. L., Liu, X., Spatz, J. M., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3001 · Cited by 98
Profile of romosozumab and its potential in the management of osteoporosis
Lim, S. Y., & Bolster, M. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s127568 · Cited by 99
Bone Disease in Thalassemia: A Molecular and Clinical Overview
Wong, P., Fuller, P. J., Gillespie, M. T., & Milat, F. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1105 · Cited by 113
Niedźwiedzki, T., & Filipowska, J. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0067 · Cited by 114
Stolina, M., Dwyer, D., Niu, Q., Villasenor, K. S., Kurimoto, P., Grisanti, M. S., Han, C.-Y. E., Liu, M., Li, X., Ominsky, M. S., et al. (2014) · Bone · doi:10.1016/j.bone.2014.07.031 · Cited by 105
Type 1 Diabetes and Osteoporosis: From Molecular Pathways to Bone Phenotype
Khan, T. S., & Fraser, L.-A. (2015) · Journal of Osteoporosis · doi:10.1155/2015/174186 · Cited by 94
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
Horne, A. M., Mihov, B., & Reid, I. R. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0404-6 · Cited by 95
Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture
Sing, C., Wong, A. Y. S., Kiel, D. P., Cheung, E. Y. N., Lam, J. K. Y., Cheung, T. T., Chan, E. W., Kung, A. W. C., Wong, I. C. K., & Cheung, C. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3448 · Cited by 94
Sclerostin: from bench to bedside
Tanaka, S., & Matsumoto, T. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01176-0 · Cited by 103
Ominsky, M. S., Brown, D. L., Van, G., Cordover, D., Pacheco, E., Frazier, E., Cherepow, L., Higgins-Garn, M., Aguirre, J. I., Wronski, T. J., et al. (2015) · Bone · doi:10.1016/j.bone.2015.08.007 · Cited by 93
Singh, S., Dutta, S., Khasbage, S. U., Kumar, T., Sachin, J., Sharma, J., & Varthya, S. B. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06095-y · Cited by 105
Wang, L., Yu, Y., Ni, S., Li, D., Liu, J., Xie, D., Chu, H. Y., Ren, Q., Zhong, C., Zhang, N., et al. (2022) · Theranostics · doi:10.7150/thno.63177 · Cited by 94
Regulation of Skeletal Homeostasis
Zaidi, M., Yuen, T., Sun, L., & Rosen, C. J. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00050 · Cited by 100
Osteoanabolic and dual action drugs
Tabacco, G., & Bilezikian, J. P. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13766 · Cited by 96
Langdahl, B. L. (2020) · Bone · doi:10.1016/j.bone.2020.115516 · Cited by 100
Self-citationRole of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders
Workgroup, O. B. O. T. E. R. O. (., Carrillo-López, N., Martínez-Arias, L., Fernández-Villabrille, S., Ruiz-Torres, M. P., Dusso, A., Cannata-Andía, J. B., Naves-Díaz, M., & Panizo, S. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00803-2 · Cited by 91
MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis
CANALIS, E. M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0920 · Cited by 104
Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition
Witcher, P. C., Miner, S. E., Horan, D. J., Bullock, W. A., Lim, K.-E., Kang, K. S., Adaniya, A. L., Ross, R. D., Loots, G. G., & Robling, A. G. (2018) · JCI Insight · doi:10.1172/jci.insight.98673 · Cited by 90
Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
Leder, B. Z. (2018) · JBMR Plus · doi:10.1002/jbm4.10041 · Cited by 89
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
Schemitsch, E. H., Miclau, T., Karachalios, T. S., Nowak, L. L., Sancheti, P. K., Poolman, R. W., Caminis, J. N., Daizadeh, N. S., Dent-Acosta, R. E., Egbuna, O. I., et al. (2020) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.19.00790 · Cited by 95
Self-citationRecent Progresses in the Treatment of Osteoporosis
Li, S., He, S., Xie, P.-Y., Li, W., Zhang, X., Li, T.-F., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.717065 · Cited by 103
Crosstalk of Brain and Bone—Clinical Observations and Their Molecular Bases
Otto, E., Knapstein, P., Jahn, D., Appelt, J., Frosch, K., Tsitsilonis, S., & Keller, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144946 · Cited by 94
Osteoporosis, bone mineral density and CKD–MBD: treatment considerations
Bover, J., Bailone, L., López‐Báez, V., Benito, S., Ciceri, P., Galassi, A., & Cozzolino, M. G. (2017) · Journal of Nephrology · doi:10.1007/s40620-017-0404-z · Cited by 103
Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis
Ramchand, S. K., & Leder, B. Z. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad496 · Cited by 86
A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction
Sato, T., Verma, S., Andrade, C. D. C., Omeara, M., Campbell, N., Wang, J. S., Cetinbas, M., Lang, A., Ausk, B. J., Brooks, D. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17099-3 · Cited by 86
Romosozumab in osteoporosis: yesterday, today and tomorrow
Wu, D., Li, L., Wen, Z., & Wang, G. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04563-z · Cited by 95
Periostin expression contributes to cortical bone loss during unloading
Gerbaix, M., Vico, L., Ferrari, S., & Bonnet, N. (2014) · Bone · doi:10.1016/j.bone.2014.10.011 · Cited by 91
Marie, P. J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1801-2 · Cited by 96
Chouinard, L., Felx, M., Mellal, N., Varela, A., Mann, P., Jolette, J., Samadfam, R., Smith, S. Y., Locher, K., Buntich, S., et al. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.08.010 · Cited by 84
Romosozumab: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01072-6 · Cited by 84
Deciphering the Relevance of Bone ECM Signaling
Alcorta-Sevillano, N., Macías, I., Infante, A., & Rodríguez, C. I. (2020) · Cells · doi:10.3390/cells9122630 · Cited by 95
Osteoporosis: An Update on Screening, Diagnosis, Evaluation, and Treatment
Sabri, S. A., Chavarria, J. C., Ackert‐Bicknell, C. L., Swanson, C. M., & Burger, E. L. (2022) · Orthopedics · doi:10.3928/01477447-20220719-03 · Cited by 103
From genetic associations to genes: methods, applications, and challenges
Qi, T., Song, L., Guo, Y., Chen, C., & Yang, J. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.04.008 · Cited by 104
Sinder, B. P., Salemi, J. D., Ominsky, M. S., Caird, M. S., Marini, J. C., & Kozloff, K. M. (2015) · Bone · doi:10.1016/j.bone.2014.10.012 · Cited by 82
Role of Osteocyte-PDL Crosstalk in Tooth Movement via SOST/Sclerostin
Odagaki, N., Ishihara, Y., Wang, Z., Hlaing, E. E., Nakamura, M., Hoshijima, M., Hayano, S., Kawanabe, N., & Kamioka, H. (2018) · Journal of Dental Research · doi:10.1177/0022034518771331 · Cited by 93
Murai, I. H., Roschel, H., Dantas, W. S., Gil, S., Merege-Filho, C., de Cleva, R., de Sá-Pinto, A. L., Lima, F., Santo, M. A., Benatti, F. B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00074 · Cited by 83
Skeletal responses to romosozumab after 12 months of denosumab
McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J., Langdahl, B. L., Shi, Y., Timoshanko, J., Libanati, C. R., Chines, A. A., & Oates, M. K. (2021) · JBMR Plus · doi:10.1002/jbm4.10512 · Cited by 83
Self-citationManagement of osteoporosis in rheumatoid arthritis patients
Hoes, J. N., Bultink, I. E. M., & Lems, W. F. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.997709 · Cited by 94
Grafe, I., Alexander, S., Yang, T., Lietman, C., Homan, E. P., Munivez, E. M., Chen, Y., Jiang, M. M., Bertin, T., Dawson, B., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2776 · Cited by 83
Fijalkowski, I., Geets, E., Steenackers, E., Van Hoof, V., Ramos, F. J., Mortier, G., Fortuna, A. M., Van Hul, W., & Boudin, E. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2782 · Cited by 82
The Utility of Biomarkers in Osteoporosis Management
Garnero, P. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0272-1 · Cited by 88
Ebina, K., Tsuboi, H., Nagayama, Y., Kashii, M., Kaneshiro, S., Miyama, A., Nakaya, H., Kunugiza, Y., Hirao, M., Okamura, G., et al. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105219 · Cited by 82
Internal Fixation of Osteoporotic Bone
Grant, K. D., Busse, E. C., Park, D. K., & Baker, K. C. (2018) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-16-00142 · Cited by 82
Cosman, F., Crittenden, D. B., Ferrari, S., Lewiecki, E. M., Jaller-Raad, J. J., Zerbini, C. A. F., Milmont, C. E., Meisner, P. D., Libanati, C. R., & Grauer, A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3439 · Cited by 87
Self-citationSolute Transport in the Bone Lacunar-Canalicular System (LCS)
Wang, L. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0414-3 · Cited by 87
Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model
Ren, Y., Han, X., Ho, S. P., Harris, S. E., Cao, Z., Economides, A. N., Qin, C., Ke, H.-Z., Liu, M., & Feng, J. Q. (2015) · The FASEB Journal · doi:10.1096/fj.14-265496 · Cited by 91
Sclerostin Enhances Adipocyte Differentiation in 3T3‐L1 Cells
Ukita, M., Yamaguchi, T., Ohata, N., & Tamura, M. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25432 · Cited by 80
A Review of Osteoporosis in the Older Adult
Alejandro, P., & Constantinescu, F. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.03.004 · Cited by 87
Graeff, C., Campbell, G. M., Peña, J. A., Borggrefe, J., Padhi, D., Kaufman, A., Chang, S., Libanati, C. R., & Glüer, C. (2015) · Bone · doi:10.1016/j.bone.2015.07.036 · Cited by 83
Self-citationGenetics of Sost/SOST in sclerosteosis and van Buchem disease animal models
Sebastian, A., & Loots, G. G. (2017) · Metabolism · doi:10.1016/j.metabol.2017.10.005 · Cited by 86
Brown, J. P., Engelke, K., Keaveny, T. M., Chines, A. A., Chapurlat, R. D., Foldes, A. J., Nogués, X., Civitelli, R., Villiers, T. D., Massari, F., et al. (2021) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4409 · Cited by 93
Self-citationBone-Vascular Axis in Chronic Kidney Disease
Evenepoel, P., Opdebeeck, B., David, K., & D’Haese, P. C. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.09.006 · Cited by 88
Romosozumab for the treatment of osteoporosis
McClung, M. R. (2018) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2018.03.002 · Cited by 78
Self-citationOh, W., Yang, Y.-S., Xie, J., Ma, H., Kim, J., Park, K. H., Oh, D. S., Park‐Min, K., Greenblatt, M. B., Gao, G., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.018 · Cited by 82
Self-citationPDGFB-based stem cell gene therapy increases bone strength in the mouse
Chen, W., Baylink, D. J., Brier‐Jones, J., Neises, A., Kiroyan, J. B., Rundle, C. H., Lau, K. ‐. W., & Zhang, X. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501759112 · Cited by 80
Treatment needs and current options for postmenopausal osteoporosis
Gennari, L., Rotatori, S., Bianciardi, S., Nuti, R., & Merlotti, D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1176147 · Cited by 85
Hormonal and systemic regulation of sclerostin
Drake, M. T., & Khosla, S. (2017) · Bone · doi:10.1016/j.bone.2016.12.004 · Cited by 77
Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application
Rauner, M., Taipaleenmäki, H., Tsourdi, E. A., & Winter, E. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040787 · Cited by 83
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old
Fuggle, N. R., Laslop, A., Rizzoli, R., Al‐Daghri, N. M., Alokail, M. S., Bałkowiec-Iskra, E., Beaudart, C., Bruyère, O., Bemden, A. B., Burlet, N., et al. (2025) · Drugs · doi:10.1007/s40265-024-02138-w · Cited by 91
Self-citationAnti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
Fabre, S., Funck‐Brentano, T., & Cohen-Solal, M. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113439 · Cited by 83
Varela, A., Chouinard, L., Lesage, E., Smith, S. Y., & Hattersley, G. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3003 · Cited by 83
Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia
Seefried, L., Baumann, J., Hemsley, S., Hofmann, C., Kunstmann, E., Kiese, B., Huang, Y., Chivers, S., Valentin, M., Borah, B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci83731 · Cited by 80
Autophagy as a target for glucocorticoid-induced osteoporosis therapy
Shen, G., Ren, H. J., Shang, Q., Qiu, T., Yu, X., Zhang, Z., Huang, J., Zhao, W., Zhang, Y., Liang, D., et al. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2776-1 · Cited by 80
Metadata
- Authors
- McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Amgen (United States) (US)
- KU Leuven (BE)
- National Institutes of Health (US)
- Centre hospitalier universitaire de Québec (CA)
- Aarhus University Hospital (DK)
- University of Liège (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-30
- Volume
- 370
- Issue
- 5
- Pages
- 412-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096627331
- Cited by
- 1,258
- References
- 16
- Citations by year
- 2026: 75 · 2025: 97 · 2024: 82 · 2023: 52 · 2022: 99 · 2021: 93 · 2020: 121 · 2019: 69 · 2018: 90 · 2017: 105 · 2016: 125 · 2015: 139 · 2014: 101
- FWCI
- 160.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, postmenopausal osteoporosis, osteopenia, bone mineral density, bone formation, bone resorption, alendronate, teriparatide, osteocytes, osteoblast activity, monoclonal antibodies, dose comparison, injection site reactions
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Calcium, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Least-Squares Analysis, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.